Digoxin: time to take the gloves off?
Abstract
Digoxin has been used for hundreds of years to aid rate control in atrial fibrillation and as a positive inotrope in heart failure. Our familiarity with digoxin has allowed it to become easily prescribed even though there are data suggesting that use of digoxin may in fact result in increased mortality and pro-arrhythmia. Within this review we explain some of the outcome data associated with digoxin use to determine if it is time to take the gloves off and examine if we should still be using this drug in the 21st century.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Digoxin use is on the decline amid the emergence of alternative therapies with preferable safety profiles.
“digoxin use is on the decline amid the emergence of alternative therapies with preferable safety profiles (Haynes et al., 2008;Eade et al., 2013).”
From Gut reactions: Breaking down xenobiotic–microbiome interactions (2019) · cites this paper as Eade et al., 2013
The citation lists haven’t been fetched yet
References 22 · Cited by 13
- Authors
- Eade, E., Cooper, R., & Mitchell, A. R. J.
- Corresponding author
- Mitchell, Andrew R.J.
- Venue
- International Journal of Cardiology
- Publisher
- Elsevier BV
- Published
- 2013-04
- Volume
- 164
- Issue
- 3
- Pages
- 365-367
- ISSN
- 0167-5273 (ISSN-L)
- OpenAlex
- W2026185684
- Cited by
- 13
- References
- 22
- Citations by year
- 2020: 2 · 2019: 3 · 2018: 1 · 2017: 1 · 2016: 1 · 2014: 2 · 2013: 1 · 2012: 2
- FWCI
- 1.10
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- Locations
- International Journal of Cardiology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Geriatrics and Gerontology › Pharmaceutical Practices and Patient Outcomes
- Keywords
- digoxin, atrial fibrillation, rate control, heart failure, positive inotropic agents, mortality, drug-induced arrhythmia, drug safety
- MeSH terms
- Anti-Arrhythmia Agents, Atrial Fibrillation, Cardiotonic Agents, Digoxin, Heart Failure, Humans, Risk Assessment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
